Description

PHARMACEUTICAL MARKET RESEARCH PROGRAM

Colchicine in Egypt: A Forgotten Generic at Three Crossroads

Niche category analysis: gout, Familial Mediterranean Fever (FMF) and cardiovascular repositioning.

Data: audited market sales, Egypt, MAT 2021 to 2025. Product and corporation rankings, MAT December 2025.

Key Figures

• Opportunity score: 58 / 100
• Market size: approximately EGP 118 million (MAT to December 2025), up from around EGP 65 million in 2021
• Growth: a four-year value CAGR of roughly 16 percent

Abstract

Colchicine is one of the oldest anti-inflammatory drugs in continuous clinical use. The molecule is derived from the autumn crocus, has no patent protection anywhere in the world and has no meaningful branded exclusivity in Egypt.

The class is small in absolute value. The Egyptian colchicine market is estimated at approximately EGP 118 million on a Moving Annual Total (MAT) basis to December 2025, up from around EGP 65 million in 2021. Unlike most Egyptian therapeutic classes, its growth is largely real: unit demand has expanded steadily as gout prevalence rises in step with metabolic syndrome, and as three distinct clinical crossroads converge on the same generic molecule.

The three crossroads

1. Gout: still the dominant indication, and still growing quietly with population and diet.
2. Familial Mediterranean Fever (FMF): a recessively inherited autoinflammatory disease with elevated prevalence in populations of Eastern Mediterranean origin, including a documented Egyptian patient pool. Colchicine remains the only proven prophylactic therapy.
3. Cardiovascular repositioning: the LoDoCo2 (NEJM 2020) and COLCOT (NEJM 2019) trials established low-dose colchicine as an evidence-based anti-inflammatory adjunct in chronic coronary disease and after myocardial infarction. This opens a small but expanding new indication share.

What the report covers

The report quantifies the class, maps its brand landscape, decomposes prescriber and indication share, and sets the findings against peer-reviewed clinical evidence. It then translates the analysis into a strategic reading for local challengers considering entry, positioning or line extension.

We assign an opportunity score of 58 out of 100: modest scale and margin structure, offset by genuine real-terms growth, distinctive MENA-specific epidemiology and a new indication trajectory.

Request the full report or a market assessment for your product. See our market research and consultation services. Related report: GLP-1 receptor agonists in the Egyptian market.